Cell Medica Limited and University College London (UCL) have entered a research collaboration agreement to develop leading-edge modified T-cell receptor (TCR) products for the treatment of cancer.
According to the agreement, Cell Medica will fund all research and development activities with an exclusive option to license all products developed in collaboration, whereas UCL will be responsible to conduct all pre-clinical and early clinical research under the guidance of a joint steering committee.
Go deeper with GlobalData
The agreement enables Cell Medica to develop breakthrough treatments for cancer using cellular immunotherapy products.
Biopharmaceutical company Cloaked Therapeutics has entered a co-development agreement with Monvida Pharmaceuticals, a pharmaceutical company, to develop TumorSelect Paclitaxel® for all oncology indications.
According to the agreement, Monvida Pharma will be responsible for developmental and commercialisation rights in China and Vietnam, while Cloaked Therapeutics will be responsible for the developmental and commercialisation rights in all other world markets.
The agreement enables the two partners to provide improved cancer care in China and Vietnam markets.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSynCore Biotech has announced a rights offering of 9.2m shares of its common stock to raise gross proceeds of $8.67m.
The company plans to use the funds to advance the development of new drugs.
Genetic testing company Singlera Genomics has raised $20m in a series A venture financing round.
The company plans to invest the funds to further advance the development and commercialisation of its genomic sequencing tests for cancer and other genetic diseases.
Sophiris Bio has priced the underwritten public offering of 6.5m shares of its common stock.
Piper Jaffray & Co. is acting as sole book-running manager and Maxim Group LLC is acting as co-manager, while Cooley LLP is acting as legal advisor for the offering.
The company expects to raise gross proceeds of approximately $26m from the offering.
The clinical-stage biopharmaceutical company plans to use the proceeds to fund clinical trials and develop topsalysin, as well as for research and development (R&D), general corporate and administrative purposes.
Image: Cell Medica Limited and University College London (UCL) have entered a research collaboration agreement. Photo: Courtesy of Stevecadman.
